CareDx, Inc (NASDAQ:CDNA) Weekly Ratings on Apr 22, 2018

April 22, 2018 - By Noel Courtney

Big Money Sentiment increased to 6.14 in 2017 Q4. It has change of 4.26, from 2017Q3’s 1.88. The ratio increased due to CareDx, Inc positioning: 3 sold and 4 reduced. 30 funds took holdings and 13 increased holdings. Investors holded 6.43 million in 2017Q3 but now own 27.90 million shares or 333.86% more.
Teton Advsrs reported 0.01% stake. Perceptive Advsr Ltd Liability Co invested 0.25% of its capital in CareDx, Inc (NASDAQ:CDNA). Spark Investment Management Ltd Liability Com holds 0.05% in CareDx, Inc (NASDAQ:CDNA) or 134,408 shs. Millennium Mgmt Limited Liability Com holds 0% of its capital in CareDx, Inc (NASDAQ:CDNA) for 45,838 shs. Wellington Mngmt Gp Llp holds 928,200 shs or 0% of its capital. G2 Prtn Management Limited Company stated it has 0.14% of its capital in CareDx, Inc (NASDAQ:CDNA). Walleye Trading Lc reported 0% of its capital in CareDx, Inc (NASDAQ:CDNA). Deutsche Retail Bank Ag reported 0% in CareDx, Inc (NASDAQ:CDNA). Gagnon Secs Limited Liability Corporation invested in 4.89% or 1.88 million shs. Awm Inv Com Inc reported 0.25% stake. Bridgeway Capital Mgmt Incorporated holds 0.01% or 111,598 shs in its capital. Bancshares Of Montreal Can has invested 0% in CareDx, Inc (NASDAQ:CDNA). Cambridge Invest Rech Advsr Inc holds 0.01% or 64,426 shs. 16,369 are held by Trexquant Inv Limited Partnership. Janney Montgomery Scott Llc holds 0% of its capital in CareDx, Inc (NASDAQ:CDNA) for 12,308 shs.

CareDx, Inc had 1 sale and 0 buys since March 27, 2018. This’s net activity of $118,035.

CareDx, Inc (NASDAQ:CDNA) Ratings Coverage

In total 2 analysts cover CareDx (NASDAQ:CDNA). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:CDNA) has 100% bullish analysts. 7 are the (NASDAQ:CDNA)’s ratings reports on Apr 22, 2018 according to StockzIntelligence Inc. The company rating was maintained by Piper Jaffray on Monday, January 8. On Monday, April 2 the stock has “Buy” rating by H.C. Wainwright. On Thursday, March 22 Piper Jaffray maintained CareDx, Inc (NASDAQ:CDNA) with “Buy” rating. On Friday, March 23 the stock has “Buy” rating by H.C. Wainwright. On Thursday, April 12 H.C. Wainwright maintained CareDx, Inc (NASDAQ:CDNA) with “Buy” rating. On Wednesday, January 31 the stock of CareDx, Inc (NASDAQ:CDNA) earned “Buy” rating by H.C. Wainwright. Listed here are CareDx, Inc (NASDAQ:CDNA) PTs and latest ratings.

12/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $12.0000 Maintain
02/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $12.0000 Maintain
23/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $12.0000 Maintain
22/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $11.0000 Maintain
31/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $12.0 Maintain
08/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $10.0 Maintain
27/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $12 Initiates Coverage On

CDNA touched $9.2 during the last trading session after $0.21 change.CareDx, Inc has volume of 145,010 shares. Since April 22, 2017 CDNA has risen 402.58% and is uptrending. CDNA outperformed by 391.03% the S&P 500.

CareDx, Inc., together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America.The firm is valued at $267.49 million. The firm operates through two divisions, CareDx and Olerup.Currently it has negative earnings. The Company’s commercialized testing solution includes the AlloMap heart transplant molecular test , a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection.

CareDx, Inc (NASDAQ:CDNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: